Isto and Arteriocyte join forces to form leading biologics player, Isto Biologics

Posted On October 19, 2016 By OrthoSpineNews In Biologics, Financial /

ST. LOUIS, Oct. 19, 2016 /PRNewswire/ — Isto Holdings, the parent company of St. Louis-based Isto Technologies – a leader in bone-regeneration technologies and cell-based therapy – has acquired medical-device company Arteriocyte Medical Systems Inc. ofHopkinton, Massachusetts, with plans to integrate the companies under the name Isto Biologics. Isto Biologics will be focused on offering evidence-based solutions to expand its spine, orthopedics, and functional-medicine product portfolios. Isto Biologics will be headquartered in St. Louis, while maintaining operations in Massachusetts.

“We’re excited to bring together two great organizations under the Isto umbrella and build upon their leading biologics platforms,” saidAnthony Chambers, Director at Thompson Street Capital Partners, which provided capital for the transaction. “Both Isto and Arteriocyte have achieved remarkable success by developing innovative, clinically-proven product offerings that help improve patient outcomes. The integrated product portfolio, combined with the expanded sales force and broader distribution network, will allow Isto Biologics to extend its reach within the spine, orthopedics, and functional-medicine markets.”

George Dunbar, current CEO of Isto Technologies, will serve as CEO of Isto Biologics. “We are grateful for the support of Thompson Street Capital Partners and excited to lead Isto Biologics into the future,” said Mr. Dunbar. “The integration of Isto and Arteriocyte presents an opportunity to leverage our combined expertise to establish a strong position in an ever-changing market and better serve our physician partners, as they work to grow their practice and meet the demands of value-based healthcare.”

Isto Biologics’ expanded, best-in-class product portfolio will feature Arteriocyte’s market-leading MAGELLAN® Autologous Platelet Separator and Isto’s bone-growth and cell-therapy products, including InQu® Bone Graft Extender & Substitute; Influx®, a natural bone-graft material; and CellPoint®, a concentrated bone marrow aspirate system.

About Isto Biologics

Isto Biologics was formed in 2016 when St. Louis-based Isto Technologies and Arteriocyte Medical Systems Inc. of Hopkinton, Massachusetts, integrated under the Isto Holdings umbrella. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The company’s best-in-class product offerings include Arteriocyte’s market-leading MAGELLAN® Autologous Platelet Separator and Isto’s bone-growth and cell-therapy products including InQu® Bone Graft Extender & Substitute; Influx®, a natural bone-graft material; and CellPoint®, a concentrated bone marrow aspirate system.

For more information, visit istobiologics.com.

Media Contact:
Jenny Reid
Director of Marketing
314-262-8039
JReid@istotech.com

Logo – http://photos.prnewswire.com/prnh/20161019/430449LOGO

SOURCE Isto Biologics

Michigan Technological University Joins Nanovation Partners in a Commercialization Agreement on Nanotube Processes

Posted On October 19, 2016 By OrthoSpineNews In Financial /

ORLANDO, FL (PRWEB) OCTOBER 19, 2016

Nanovation Partners, LLC and Michigan Technological University today announced a partnership agreement for commercialization of processes to nano-texturize medical implants. These advanced processes can simultaneously increase bone ingrowth and provide an antimicrobial barrier. The collaboration agreement extends Nanovation Partner’s leadership in commercialization of nano-texturing technology.

Craig Friedrich, PhD, Director of Michigan Tech’s Multi-scale Technologies Institute, commented, “What we’re developing is a surface treatment that’s more straightforward and economical than other processes. It speeds healing and is applicable to a broad range of implants. With this process, in conjunction with the technologies developed at other leading nano-technology universities and companies already in partnership with Nanovation Partners, we can fight infection and reduce inflammation. Our partnership with Nanovation Partners will speed and broaden the transfer of this technology to provide a clinical benefit for a broad range of patients.”

With this latest collaboration, Nanovation Partners has aligned with another well-published, recognized leader in the development of titanium dioxide (TiO2) nanotubes for modifying the surfaces of medical implants. It builds on Nanovation Partners’ growing list of partnerships with academic researchers at the University of California San Diego (UCSD), Washington State University (WSU), and University of Central Florida (UCF), and further broadens the company’s portfolio of five Issued and over 20 pending U.S. and international patents for nanotexturing processes and structures.

Researchers at Michigan Technological University and Washington State University have been issued separate U.S. patents for nanotexturing processes and structures that improve bone growth and provide anti-microbial properties, addressing both initial and long-term infections following implantation. The agreements with these institutions give Nanovation Partners, in part, exclusive rights to license the technologies to medical device companies in all medical areas.

“The partnership with Michigan Tech builds on Nanovation Partners’ strategic collaborations with leaders in nanotexturing technology,” said Dan Justin, President and CEO of Nanovation Partners. “We are first licensing technologies focused on nanotexturing existing implant surfaces, then, when applicable, licensing nanotechnologies that further enhance the textured surface. Our licenses with the four universities extend into all areas of medicine including orthopedics, cardiovascular, and neurovascular. Having demonstrated superior properties to other nanotextured and traditional implant surfaces in numerous in vivo and in vitro studies, our nanotube structure addresses all three major deficiencies of traditional implant material surfaces, by increasing hydrophilicity, enhancing osseointegration and by providing a surface that is unfriendly to pathogenic microbes. The agreement with Michigan Tech extends Nanovation Partners lead in developing nanotexturing technology for clinical use.”

Mr. Justin continued, “In addition to the first generation of nanotechnologies that enhance implants by nanotexturing their surfaces, the next generation of licensed technologies from our four research institution partners can be used as drug and antimicrobial delivery systems. For example, Michigan Tech’s technology has demonstrated extended release of the anti-inflammatory drug sodium naproxen after implant surgery in a study published in the journal RSC Advances. The technology may also be used on a variety of implants to reduce inflammation and promote healing. All of these technologies are now available for further development and licensing, and Nanovation Partners is actively seeking medical device partners who are interested in bringing this innovative approach to patients.”

Nanovation Partners has also recently partnered with N2 Biomedical of Bedford, Massachusetts, a leading ISO-13485 certified surface treatment provider, who can perform the nanotexturing process on a service basis for interested device manufacturers.

Discover Nanotechnology at NASS (Booth #1837) in Boston, MA where Nanovation Partners will be exhibiting, October 26th through October 29th.

For more information, please contact Dan Justin (info(at)nanovationpartners.com), President and CEO of Nanovation Partners, LLC.

Michigan Technological University is a leading public research university developing new technologies and preparing students to create the future for a prosperous and sustainable world. Michigan Tech offers more than 120 undergraduate and graduate degree programs in engineering; forest resources; computing; technology; business; economics; natural, physical and environmental sciences; arts; humanities; and social sciences.

Nanovation Partners LLC sponsored early research at the University of California at San Diego (UCSD) in the lab of Sungho Jin, PhD. This research showed enhanced osseointegration and reduced implant surface infection by forming tiny rows of metal oxide nanotubes on the implant surfaces. A comprehensive patent portfolio has since begun issuing with claims that cover a wide range of processes and structures. Nanovation Partners has also licensed Intellectual Property from Washington State University (WSU) related to antimicrobials with silver nano-particles on nanotubes and other nanostructures, the University of Central Florida (UCF) and Michigan Technological University related to nanotube processing.

Manufacturer ramps up Dayton hiring with new strategy

Posted On October 19, 2016 By OrthoSpineNews In Financial /

Oct 19, 2016 – Tristan Navera

NuVasive Inc. is picking up the pace of hiring in Dayton, where it is developing a new manufacturing facility.

The medical manufacturing company needs to hire about 100 people between now and the end of the first quarter of 2017. And it is still seeking almost two thirds of the talent for the ramp-up of its new West Carrollton facility. For a company relatively new to the Dayton area, that has been a challenge, said Ruben Perez, NuVasive’s senior director of manufacturing.

“We started up the first few machines and we’re producing now,” Perez said. “As we get ready for 2017, we have an even more aggressive schedule. But we can see we’ve got a need for a lot of qualified folks and we need to get ahead of it.”

NuVasive — which makes spinal implants, fixation hardware and surgical instruments — is building a $45 million global manufacturing facility along Liberty Lane in West Carrollton, which will open in late 2017. The site will bring over 125 employees from its Fairborn site and also mean another 200 hires. The 180,000-square-foot site will be where it manufactures all of its implants, fixation hardware and surgical instruments.

READ THE REST HERE

RTI Surgical® Schedules 2016 Third Quarter Earnings and Conference Call for Oct. 25, 2016

Posted On October 18, 2016 By OrthoSpineNews In Financial /

October 18, 2016

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical Inc. (RTI) (Nasdaq: RTIX), a global surgical implant company, announced today that it plans to release financial results from the third quarter 2016 on Tuesday, Oct. 25, 2016, prior to the market open.

RTI will host a conference call and simultaneous audio webcast to discuss second quarter results at 8:30 a.m. ET the same day. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International). The webcast can be accessed through the investor section of RTI’s website at www.rtix.com. A replay of the conference call will be available on RTI’s website for one month following the call.

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website atwww.sec.gov.

Contacts

RTI Surgical Inc.
Robert Jordheim
Executive Vice President,
Chief Financial Officer
rjordheim@rtix.com
or
Wendy Crites Wacker, APR
Vice President, Global Communications
wwacker@rtix.com
386-418-8888

Tecomet Inc. Announces Acquisition of Mountainside Medical

Posted On October 18, 2016 By OrthoSpineNews In Financial /

WILMINGTON, Mass., Oct. 17, 2016 /PRNewswire/ — Tecomet Inc., a global provider of innovation, design & development services and manufacturing solutions for OEMs in the medical and aerospace & defense industries, today announced the acquisition of Mountainside Medical, a supplier of complex, high precision medical device components and instruments used in minimally invasive surgical devices.

Headquartered in Boulder, CO, Mountainside’s products span across a wide range of precision machined components for the minimally invasive market, including laparoscopic instruments and jaws, orthopedic/neuro-navigation instrumentation, and electrosurgical instruments. The company has invested heavily in research & development, precision machining technology, automation and assembly solutions. Mountainside has developed into a full service manufacturing partner to engineer, design, and manufacture current and next-generation surgical components. The company has a strong pipeline of new products currently in the development stage.

Mark Kemp, Chief Executive Officer, of Tecomet, said, “Achieving a leadership position in the minimally invasive surgical market is a key strategic priority of Tecomet, and the acquisition of Mountainside Medical greatly expands our capabilities and scale in this highly attractive end market. Mountainside’s dedication to innovation, design and development services, prototyping, and precision component manufacturing solutions combined with intimate customer service align perfectly with Tecomet’s strategy and culture. We are excited to partner with Mountainside’s management and employees to further establish collaborative partnerships with new and existing customers.”

Peter Neidecker, Co-Founder of Mountainside, said, “Since my wife Susan and I founded the company we have followed a philosophy of constant innovation. Mountainside’s experienced management team is supported by talented employees who deliver results through a combination of continuous improvement and growth initiatives. With Tecomet’s global footprint, manufacturing capabilities and expertise in design and engineering, Mountainside is very well positioned for future growth.”

About Tecomet
Founded in 1964 and based in Wilmington, MA, Tecomet is a global manufacturer of high precision implants, surgical instruments, trauma plates and photochemical etched products for medical device customers. Tecomet uses its industry-leading prototyping and engineering capabilities to produce highly complex products that provide innovative solutions for its customers’ most demanding products and applications. Tecomet is also a leading manufacturer of precision components to the aerospace & defense industry, producing products used in aircraft engines, missile & satellite propulsion systems, vision systems, and infrared applications. For more information about Tecomet, please visit www.tecomet.com.

Contact: Chris Tofalli
Chris Tofalli Public Relations
914-834-4334

SOURCE Tecomet Inc.

bigstock-Business-Handshake-Agreement-P-83033555-740x431.jpg

INTERMED RESOURCES AND Z-MEDICAL ANNOUNCE AGREEMENT WITH HEALTHTRUST

Posted On October 18, 2016 By OrthoSpineNews In Financial /

11.10.2016

InterMed Resources will distribute spinal implants manufactured by Z-Medical, a company based in Tuttlingen, Germany to HealthTrust (legally known as HealthTrust Purchasing Group, L.P.), a leading group purchasing and total cost management organization that serves nearly 1,600 acute care facilities nationwide.

Under the agreement, Z-Medical will sell its MIS Z-Pedicle Screw System at a contracted price for distribution exclusively through InterMed Resources TN LLC to HealthTrust member facilities throughout the United States.

Z-Medical’s MIS Z-Pedicle Screw System offers surgeons an ideal solution for their indication specific needs. It includes pre-sterilized implants, only one instrument set and an innovative screw design enabling surgeons to efficiently and cost effectively address the most common pathologies. It was designed for a minimally-invasive approach for less tissue disruption, blood loss and trauma and is approved for Degenerative, Trauma, Tumor and Deformity application.

About InterMed Resources TN
InterMed Resources, located in Brentwood, Tennessee, is a minority-owned business that provides national and corporate consulting and contract management services to a variety of medical device manufacturers and suppliers focused on acute care, surgery centers, hospitals, long-term care and physician markets. InterMed specializes in representing innovative medical device companies and suppliers in small and medium business market segments. Its management team has extensive clinical, sales, distribution and national contracting experience (over 50 years collectively) in medical devices.

About Z-Medical
Z-Medical^® GmbH + Co. KG, based in Tuttlingen, Germany, is a privately financed and held medical device company that designs, develops, manufactures and markets innovative implants and surgical instruments in the section of Spine, Hand & Foot and Arthroscopy. The company’s U.S. subsidiary was established in Atlanta, Georgia. Z-Medical implants stand for precision, are sterile packaged and ready for surgery. http://www.z-medicalUSA.com/

Z-Medical is actively recruiting regional distributors to capitalize on this expansion to its hospital network. For Z-Medical information please contact, René Rothacker, Director International Business Development / U.S. Operations, International Cell 0049 170 453 4423, or r.rothacker@z-medical.de

About HealthTrust
HealthTrust (legally known as HealthTrust Purchasing Group, L.P.) is committed to strengthening provider performance and clinical excellence through an aligned membership model and the delivery of total cost management solutions, including supply chain solutions and a contract and service portfolio unparalleled in quality, scope and value. HealthTrust (www.healthtrustpg.com) serves 1,600 acute care facilities, 800 ambulatory surgery centers and members in more than 10,600 other locations, including physician practices, long-term care and alternate care sites. Headquartered in Brentwood, Tennessee, HealthTrust is closely integrated with the proven capabilities of Parallon Business Solutions, LLC (www.parallon.com), a leading provider of healthcare business and operational services, including revenue cycle management, workforce and technology solutions. On Twitter @healthtrustpg and @parallonconnect

Global Medical Ceramics Market Growth at CAGR of 7.06%, 2016-2020: Challenges, Trends & Drivers – Key Vendors are 3M ESPE, CoorsTek Medical, Straumann & Stryker – Research and Markets

Posted On October 17, 2016 By OrthoSpineNews In Financial /

October 17, 2016

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Medical Ceramics Market 2016-2020”report to their offering.

The global medical ceramics market to grow at a CAGR of 7.06% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global medical ceramics market for 2016-2020. To calculate the market size, the report considers the revenue generated through the sales of medical ceramic products in applications such as orthopedic, implantable devices, dental application, surgical and diagnostic instrument, and therapeutic treatment of cancer by considering 2015 as the base year. The report also includes a discussion of the key vendors operating in this market.

Original equipment manufacturers (OEMs) in some industries prefer customized ceramics for their components. The production of customized components is not always feasible as customization increases the production cost and time.

Market players, instead of mass-producing simple shapes, prefer to manufacture ceramics according to the buyers (OEM) requirement. Such customized production of technical ceramics requires additional efforts during the stages of molding and formulation of components. Specific customization needs for different applications such as bone void fillers, spinal fusion, bone augmentation, osteoconductive scaffold for bone regeneration and spine cage inserts are acting as a trend for the growth of the ceramic medical market.

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Key vendors

3M ESPE
CoorsTek Medical
Straumann
Stryker

Other prominent vendors

Amedica
APC International
BCE Special Ceramics
CeraRoot

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Market segmentation by type

Part 07: Market segmentation by applications

Part 08: Geographical segmentation

Part 09: Market drivers

Part 10: Impact of drivers

Part 11: Market challenges

Part 12: Impact of drivers and challenges

Part 13: Market trends

Part 14: Vendor landscape

Part 15: Key vendor analysis

Part 16: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/bb8frx/global_medical

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Ceramics

Intuitive Surgical Reports New Employee Option Grants for October 2016

Posted On October 17, 2016 By OrthoSpineNews In Financial /

SUNNYVALE, Calif., Oct. 14, 2016 (GLOBE NEWSWIRE) — Intuitive Surgical, Inc. (ISRG) today reported that equity awards approved by the Compensation Committee of the Board of Directors, which consists entirely of Independent Directors, were made to 66 new employees. Pursuant to NASDAQ Marketplace Rule 5635(c)(4), the equity awards were granted under the Intuitive Surgical, Inc. 2009 Commencement Incentive Plan, which the Board of Directors of Intuitive Surgical, Inc. adopted for the granting of equity awards to new employees. In accordance with NASDAQ rules, these grants were made under an equity incentive plan without shareholder approval. NASDAQ rules require a public announcement of equity awards to be made under this type of plan. 66 employees were granted a combination of Restricted Stock Units (RSUs) and Stock Options to purchase an aggregate of 10,221 shares of the Company’s common stock; 5,072 of the shares granted were Stock Options and 5,149 of the shares granted were RSUs. Both the RSUs and Stock Options vest over four years. The Stock Options expire in 10 years assuming continued employment. No officers received any award under this plan. The exercise price for the Stock Options granted is $718.04 which was the closing price of Intuitive Surgical, Inc.’s common stock on the NASDAQ Global Market as such price was reported by NASDAQ on October 7, 2016. The Company’s policy is to issue RSUs and Stock Option grants to new employees, where equity makes sense, on the fifth business day of every calendar month.

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (ISRG), headquartered in Sunnyvale, California, is the global technology leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets robotic technologies designed to improve clinical outcomes and help patients return more quickly to active and productive lives. The Company’s mission is to extend the benefits of minimally invasive surgery to the broadest possible base of patients. Intuitive Surgical – Taking surgery beyond the limits of the human hand™.

About the da Vinci® Surgical System

The da Vinci® System is a breakthrough surgical platform designed to enable complex surgery using a minimally invasive approach. The da Vinci® System consists of an ergonomic surgeon console, a patient-side cart with four interactive robotic arms, a high-performance vision system and proprietary EndoWrist® instruments. Powered by state-of-the-art robotic and computer technology, the da Vinci® System is designed to scale, filter and seamlessly translate the surgeon’s hand movements into more precise movements of the EndoWrist® instruments. The net result is an intuitive interface with breakthrough surgical capabilities. By providing surgeons with superior visualization, enhanced dexterity, greater precision and ergonomic comfort, the da Vinci Surgical System makes it possible for more surgeons to perform minimally invasive procedures involving complex dissection or reconstruction. This ultimately has the potential to raise the standard of care for complex surgeries, translating into numerous potential patient benefits, including less pain, a shorter recovery and quicker return to normal daily activities.

Intuitive®, da Vinci®, da Vinci S®, da Vinci® Si™, InSite® and EndoWrist® are trademarks or registered trademarks of Intuitive Surgical, Inc.

For more information, please visit the company’s web site at www.intuitivesurgical.com.

Safe Orthopaedics Reports Its Revenue for the First 9 Months of 2016 and Its Cash Position

Posted On October 13, 2016 By OrthoSpineNews In Financial /

October 13, 2016 – ERAGNY-SUR-OISE, France –(BUSINESS WIRE)

SAFE ORTHOPAEDICS (FR0012452746 – SAFOR) (Paris:SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments for back surgery, has today released its revenue for the first nine months of 2016 and its cash position at September 30, 2016.

in thousands of euros	9m 2016	9m 2015	Change
France	855	738	+16%
Rest of the world (excluding United States)	770	822	-6%
*Total adjusted revenue**	1,625	1,560	+4%
United States (discontinued operations)	100	375	-73%
Total revenue	1,726	1,935	-11%
Cash position (in millions of euros, at September 30)	4.3	7.6

*Adjusted for operations in the United States discontinued effective March1, 2016.

In the first nine months of 2016, revenue adjusted for operations in the United States grew 4% to €1,625 thousand, compared with €1,520 thousand in the same period of 2015. Growth in France continued, with revenue moving up 16% to €855 thousand in the first nine months of 2016, compared with €738 thousand in the same period of 2015.

in thousands of euros	Q3 2016	Q3 2015	Change
France	256	232	+10%
Rest of the world (excluding United States)	165	280	-41%
*Total adjusted revenue**	421	512	-18%
United States (discontinued operations)	0	116	-100%
Total revenue	421	628	-33%

*Adjusted for operations in the United States discontinued effective March1, 2016.

In the third quarter of 2016, Safe Orthopaedics’ adjusted revenue came to €421 thousand, down from €512 thousand in the same period of the previous year. Quarterly revenue in France totaled €256 thousand, up from €232 thousand in the year-earlier period. This 10% increase reflected the success of the Group’s strategy of focusing on a direct sales model.

The French market continued to grow, and sales are expected to reap the benefit of additions to its sales force. In the fourth quarter, Safe Orthopaedics plans to manage its sales directly in Switzerland. The revenue contraction in export markets reflected some major disparities. In particular, the third-quarter 2016 figure was depressed by a credit note issued in connection with the termination of a relationship with an underperforming distributor in Switzerland.

What’s more, following on from its expansion into South America, Safe Orthopaedics intends to continue establishing a presence in emerging markets with great commercial potential. For example, the regulatory approval process for Safe Orthopaedics’ products is nearing completion in Russia (commercial launch scheduled for the first half of 2017).

“Although our third-quarter 2016 performance in export markets was disappointing, our sales have really gained pace in areas where our marketing efforts are focused on our most highly differentiated technologies. Our products for treating trauma (SteriSpine^TMPS and Oak screw) and degenerative conditions by means of a minimally invasive technique (Cypress screw) are very popular with our customers, as five surgeons recently explained in their EuroSpine presentations”, said Pierre Dumouchel, Chief Executive Officer of Safe Orthopaedics. “The refocusing of our business in March 2016, the new hires strengthening our sales and marketing teams, and the promotion of our unique technologies are set to pay off in the near future”.

Cash position

At September 30, 2016, Safe Orthopaedics had €4.3 million in cash, not including the €650 thousand raised from the issue of a new tranche of OCABSA notes on September 29, 2016.

For the record, Safe Orthopaedics held €4.3 million in cash at June 30, 2016 and €5.9 million at December 31, 2015.

Next Financial Release

Fourth-quarter 2016 revenue: Thursday January 19, 2017 (after market close)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the SteriSpine™ Kits are CE-marked and FDA cleared. The company is based at Eragny-sur-Oise (France), and has 34 employees.

For more information, visit: www.SafeOrtho.com

View source version on businesswire.com:http://www.businesswire.com/news/home/20161013006217/en/

Safe Orthopaedics
Thierry Lambert
CFO
Tél. : +33 (0)1 34 21 50 00
investors@safeorthopaedics.com
or
NewCap
Investor Relations
Julien Perez / Valentine Brouchot
or
Nicolas Merigeau
Media Relations
Tél. : +33 (0)1 44 71 94 94
SafeOrtho@newcap.eu

This article was originally distributed via Business Wire. Business Wire, Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

Vexim: +37% Sales Increase to €13.3 Million as of September 30, 2016 (9 Months)

Posted On October 13, 2016 By OrthoSpineNews In Financial /

October 13, 2016

TOULOUSE, France–(BUSINESS WIRE)–

VEXIM (Paris:ALVXM) (FR0011072602 – ALVXM / PEA‐PME), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces its consolidated sales results for the third quarter 2016.

« Vexim continues to develop according to its plan. Our results confirm the objectives set as the SpineJack® is becoming a reference on the spine trauma market. We are aiming at a market share of 10% in Europe by the end of 2016 and continue to strengthen our presence namely in Germany. Outside of Europe, we are also extending our market coverage with new developments in Australia and South Africa, a trend that will be reinforced in 2017. As announced during our half-year result publication, we are still confident in achieving profitability in the second-half of 2016 while maintaining a solid cash position”, said Vincent Gardès, Vexim’s CEO.

Continued growth in the third quarter 2016


Revenues (in million of euros as of September, 30^th)
Quarterly sales			Cumulated sales (9 months)
Q3 2016	Q3 2015	Variation (%)	2016	2015	Variation (%)
4.700	3.561	+32%	13.265	9.657	+37%

Vexim’s sales reached €4.7 million over the third quarter 2016, up 32% compared with the same period in 2015. These results are in line with the objectives set for the full year 2016 and reflect Vexim’s strong performance on all its markets.

Vexim’s growth in Europe remains solid, up 37% in the first nine months of the year. Vexim continues to gain market shares in France and pursues its development in Germany.

There is also a growing interest in the SpineJack® technology outside of Europe, where Vexim’s cumulated sales increased by 51% as of September 30, 2016. The company recently announced the signature of a distribution agreement in South Africa¹ and the registration of its products SpineJack® and Masterflow™ in Australia².

As of September 30, 2016, the total number of implants sold since the launch of the SpineJack® in 2011 came over 38,150 units, representing approximately 18,175 patients treated.

Click on the following link to view the presentation of Vexim’s half-year 2016 results:
http://www.vexim.com/us/shareholder-area/investors-guide/

Financial reporting schedule:
2016 sales results: January 17^th, 2017³

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital⁴ and from BPI public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The company also developed the Masterflow^TM, an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure. The company counts 64 employees, including its own sales teams in Europe and a network of international distributors.

VEXIM has been listed on Alternext Paris since May 2012. For further information, please visit www.vexim.com

SpineJack® ⁵, a revolutionary implant for treating Vertebral Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spinal surgery and worldwide patent protection through to 2029.

Masterflow^TM ², a high-performance orthopedic cement delivery system

The Masterflow^TM is an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure for treating vertebral compression fractures. The device provides a better control of the injection of biomaterials into the spine. A complement of the SpineJack®, the Masterflow^TM stands out for being both easy to use and precise, particularly in its ability to stop the cement delivery instantly without inertia. The Masterflow^TM contributes to reducing pain in patients. Its first sales were recorded in the U.S. in February 2015, and the system has also received the CE marking in February 2015, a mandatory conformity mark for products marketed in Europe.

Name : VEXIM
ISIN code : FR0011072602
Ticker : ALVXM

¹ Press release: http://www.vexim.com/us/vexim-signs-a-distribution-agreement-with-creatori-health-and-expands-its-market-to-south-africa/

² Press release: http://www.vexim.com/us/vexim-announces-the-registration-of-its-products-spinejack-and-masterflow-in-australia/

³ Indicative date, subject to changes.

⁴ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

⁵ This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.

Contacts

VEXIM
Vincent Gardès, CEO
José Da Gloria, Chief Financial Officer
investisseur@vexim.com
+33 5 61 48 48 38
or
PRESS
ALIZE RP
Caroline Carmagnol / Wendy Rigal
vexim@alizerp.com
+33 1 44 54 36 66
+33 6 48 82 18 94